HPV Vaccination in Africa- New Delivery Schedules Alias The HANDS HPV Vaccine Trial

NCT ID: NCT03832049

Last Updated: 2022-03-31

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 1720 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-09-14
• Study Completion Date: 2024-06-30

Brief Summary

A randomized, observer-blind non-inferiority trial to evaluate alternative human papillomavirus (HPV) vaccination schedules in young females in West Africa.

Detailed Description

This study is a randomized, open-label, single-centre, phase 3 non-inferiority clinical trial of the Gardasil 9 vaccine. It will be undertaken in three female cohorts (15 to 26 years old; 9 to 14 years-olds and 4 to 8 year-olds). In total 1720 female participants will be recruited in a rural setting in The Gambia, West Africa.

The Gardasil 9 vaccine is a recombinant L 1 VLP vaccine containing HPV types 6, 11,16,18,31,33,45,52 and 58 VLP. It is licensed by both European Medicines Agency and the US Food and Drug Administration as a two or three dose schedule to 9 to 14 year olds and as a three dose schedule to 15 to 26 years olds. The license covers both males and females. The vaccine is not currently licensed for those under 9 years of age and it is not licenced in The Gambia.

All females within the 15 to 26 year-old cohort will receive three doses of Gardasil 9 at 0, 2 and 6 months and represent the reference group for the purposes of the serological non-inferiority analysis. This is the only group for which efficacy data for the vaccine are available. Females in the 9 to 14 year old and 4 to 8 year old cohorts will be randomized to receive either one or two doses of Gardasil 9. In both groups, the two doses will be administered at 0 and 6 months.

The primary and secondary immunogenicity objectives will be analysed based on serological Samples taken 4 to 6 weeks after the last dose of vaccine received according to group. Additional analysis will be undertaken at 12, 24 and 36 months. The Sampling schedule is aligned with the schedule in other immunogenicity trials to facilitate comparison and potential immunobridging to future one-dose efficacy data. In addition, the stability of the antibody concentrations between 12 and 24 and again between 24 and 36 months according to schedule and age-group aims to allow longer term predictions regarding the maintenance of antibody concentration to be made.

A Sub-study will be undertaken within the main trial to compare in detail early immunological events taking place following Gardasil 9. The quantitative and qualitative changes in these events following a first and following subsequent doses of the vaccine and also according to age will be assessed and related to the early and long-term antibody concentrations induced by the vaccine. There are currently no data exploring the basis for the progressive increase in the immunogenicity of the HPV vaccines apparent with decreasing age. These may have their origins in the early innate response following vaccination-which will be assessed at a cellular as well as transcriptomic level, as well as in the subsequent adaptive profile.

Similarly, the cellular basis for the sustained seropositivity induced by the HPV vaccines even apparent following a single vaccine dose is little understood. The window onto which plasmablasts and memory B-cell populations in the circulation is transient following vaccination. However, enumerating and characterizing these populations and relating them in the same way to early and long term antibody concentration aims to provide insight into the relative roles of these populations and how they are influenced by the age of the vaccine and the number of vaccine doses received.

Individuals in the sub-study will contribute serological data to the main trial and will be followed up in the same way but will be consented for one additional blood sample after each vaccination. Up to 120 participant in each group in the main trial will be randomized to groups A, B or C, with 40 participants in each of these groups. This number aims to generate a dataset of at least 30 analyzable individuals per schedule and age group.

Conditions

Human Papillomavirus Vaccine

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: SINGLE

Study Groups

15 to 26 years - 3 dose

9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses

Group Type: ACTIVE_COMPARATOR

9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses

Intervention Type: BIOLOGICAL

0.5mL intramuscular dose - 3 doses (0, 2 and 6 months)

9 to 14 years - 2 dose

9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses

Group Type: EXPERIMENTAL

9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses

Intervention Type: BIOLOGICAL

0.5mL intramuscular dose - 2 doses (0 and 6 months)

4 to 8 years - 2 dose

9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses

Group Type: EXPERIMENTAL

9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses

Intervention Type: BIOLOGICAL

0.5mL intramuscular dose - 2 doses (0 and 6 months)

9 to 14 years - 1 dose

9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose

Group Type: EXPERIMENTAL

9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose

Intervention Type: BIOLOGICAL

0.5mL intramuscular dose - 1 doses (0 months)

4 to 8 years - 1 dose

9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose

Group Type: EXPERIMENTAL

9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose

Intervention Type: BIOLOGICAL

0.5mL intramuscular dose - 1 doses (0 months)

Interventions

9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses

0.5mL intramuscular dose - 3 doses (0, 2 and 6 months)

Intervention Type: BIOLOGICAL

9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses

0.5mL intramuscular dose - 2 doses (0 and 6 months)

Intervention Type: BIOLOGICAL

9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose

0.5mL intramuscular dose - 1 doses (0 months)

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Signed/thumb-printed informed consent obtained from the participant's parent (4 to 17 year-olds) or signed/thumb-printed informed consent obtained from the participant (18 years and above)
• Signed/thumb-printed assent obtained from the participant (12 to 17 year-olds only).
• Documented verbal assent obtained from the participant (6 to 11 year-olds only)
• Participant is of female sex (based on participant/parent self-report)
• Participant is between 4 and 26 years of age inclusive
• Parent/participant is willing and judged able to comply with the necessary study procedures
• Parent/participant does not have established plans to leave the study area for a prolonged period/indefinitely during the 3 year follow-up period
• Participant is resident within the study area (no fixed boundaries will be set and decisions will be made on a case-by-case basis by the study team taking into account not only distance but also transport links, accessibility for the purposes of safety data collection, willingness of the parent/participant to travel)
• Place of residence of the participant must be readily identifiable

Exclusion Criteria

• Receipt of other investigational medicinal products (IMP) in a period of 12 months prior to the day of randomization and vaccination or plans to receive IMP during the trial.
• Presence of significant chronic health problems requiring long-term medication or medical follow-up including respiratory, cardiac, gastrointestinal, hepatic, renal, neurological, musculoskeletal, haematological or other conditions based on parental history and physical examination of the participant. Participants with known sickle cell disease (but not sickle cell trait) will be excluded.
• History of severe allergic reactions to any prior vaccine or to any component of the study vaccine (including alum (amorphous aluminum hydroxyphosphate sulphate), yeast or Benzonase). Severe allergic reactions are defined as reactions requiring urgent medical intervention including reactions with any degree of cardiorespiratory compromise. The occurrence of a mild rash without other associated symptoms or signs does not generally represent an exclusion. Allergic reactions should be distinguished from the local and systemic reactogenicity expected in the first few days following vaccination which is not an exclusion to vaccination
• Prior receipt of an HPV vaccine
• Receipt of any vaccine in the 28 days prior to randomization and vaccination‡
• History of thrombocytopenia or coagulation disorders which represent contraindications in intramuscular (IM) vaccination
• Known congenital or acquired immune deficiency or history strongly indicative of abnormal immune function. HIV testing will not be undertaken as part of the routine screening procedures due to the relatively low prevalence of HIV expected in the population (~1-3%) and the established safety and immunogenicity profile of Gardasil in HIV positive individuals.
• Receipt of intravenous immunoglobulins or blood products within a period of 12 months prior to the day of randomization and vaccination or plans to receive such products during the course of the trial.
• Pregnancy (females in the 15 to 26 years old cohort will require a urine pregnancy test as part of the screening procedures and will also have a urine pregnancy test undertaken prior to the second and third vaccination and vaccination delayed if pregnancy is confirmed. A minimum of 42 days from the end of pregnancy (irrespective of outcome) will be left before the delayed vaccination is administered. Participants who are pregnant at initial screening will not be re-screened but will be defined as screen failures. Breast feeding is not an exclusion criterion
• Intention to become pregnant within six months of enrollment in the trial. Confirmation regarding the use of a reliable method of contraception is not required but females who are actively seeking to become pregnant within six months of enrollment will be excluded.
• Fever (>38.0°C) on the day of vaccination or documented fever (>38.0°C) within the 24 hours preceding vaccination
• Abnormal (Grade > 1) vital signs (heart rate, respiratory rate, blood pressure) on the day of vaccination
• Positive rapid diagnostic test (RDT) or blood film for malaria on the day of vaccination
• Clinically-significant (Grade > 2) acute illness present on the day of vaccination (minor illnesses including upper respiratory tract infections, diarrhoeal illness and skin complaints not associated with fever or significant systemic upset are not in themselves reasons for exclusion)

• Minimum Eligible Age: 4 Years
• Maximum Eligible Age: 26 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Public Health England

OTHER_GOV

Sponsor Role: collaborator

University of Cambridge

OTHER

Sponsor Role: collaborator

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role: collaborator

London School of Hygiene and Tropical Medicine

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ed Clarke, MB ChB PhD

Role: PRINCIPAL_INVESTIGATOR

Medical Research Council @ LSHTM

Locations

Ed Clarke

Banjul, Outside U.S. and Canada, The Gambia

Countries

The Gambia

Other Identifiers

SCC 1597

Identifier Type: -

Identifier Source: org_study_id